Agile Therapeutics, Inc. (AGRX) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Agile Therapeutics, Inc. (NASDAQ:AGRX) released its quarterly earnings data on Friday. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02, Briefing.com reports. During the same period in the previous year, the firm earned ($0.29) EPS.
Shares of Agile Therapeutics (AGRX) traded up 7.61% on Friday, reaching $4.95. The company’s stock had a trading volume of 914,108 shares. The stock’s market cap is $142.59 million. The firm has a 50 day moving average price of $4.10 and a 200-day moving average price of $3.17. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $8.15.
In other news, insider Renee Selman acquired 53,333 shares of the business’s stock in a transaction dated Thursday, May 11th. The shares were acquired at an average cost of $3.68 per share, with a total value of $196,265.44. Following the completion of the acquisition, the insider now owns 53,333 shares of the company’s stock, valued at $196,265.44. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Alfred Altomari acquired 10,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was purchased at an average cost of $3.51 per share, for a total transaction of $35,100.00. Following the completion of the acquisition, the chairman now directly owns 151,587 shares of the company’s stock, valued at approximately $532,070.37. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by corporate insiders.
Several research firms recently commented on AGRX. Royal Bank Of Canada set a $8.00 price objective on Agile Therapeutics and gave the company a “buy” rating in a research report on Sunday, July 16th. HC Wainwright assumed coverage on Agile Therapeutics in a research report on Wednesday, July 19th. They issued a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald raised their target price on Agile Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 4th. ValuEngine raised Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Finally, Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $9.93.
WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/agile-therapeutics-inc-agrx-releases-quarterly-earnings-results-beats-expectations-by-0-02-eps/1462911.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.